NovoCure Ltd

NVCR

NovoCure Ltd

NVCR

Insider Sentiment (TTM):

Last Purchase:2025-09-05Last Sale:2026-06-04Shares Purchased (TTM):81,550Shares Sold (TTM):204,034

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:93,475,669Shares Outstanding:114,149,838Institutional Ownership Pct.:81.89%

Earnings Market Reaction:

Filing Date:2026-07-23Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	94	88	94	342	150	127	164	185	165	454	241	155
Held To Maturity Securities Current	347	344	354	691	762	802	796	774	786	416	670	766
Restricted Cash Current	10	10	10	3	3	2	2	4	4	4	2	2
Accounts Receivable Net Current	99	93	89	85	90	85	74	67	65	65	61	65
Inventory Net	42	43	41	39	40	39	35	39	40	42	38	37
Assets Current	639	632	647	1,200	1,083	1,089	1,107	1,095	1,093	1,003	1,034	1,048
Assets Noncurrent
Property Plant And Equipment Net	75	76	78	80	80	80	78	73	66	59	51	46
Operating Lease Right Of Use Asset	44	45	47	48	48	49	27	28	29	33	35	29
Other Assets Noncurrent	11	11	11	12	16	14	15	12	12	15	14	12
Assets Noncurrent	157	156	158	161	163	160	134	127	119	119	112	98
Assets	795	788	804	1,361	1,246	1,249	1,241	1,222	1,212	1,121	1,146	1,146
Liabilities And Stockhold…
Liabilities Current
Convertible Notes Payable Current	-	-	0	561	560	559	558	557	-	-	0	-
Accounts Payable Trade Current	131	127	122	119	104	95	105	91	90	84	94	80
Liabilities Current	221	218	223	776	750	743	756	735	169	160	179	157
Long Term Debt Noncurrent	-	-	-	-	-	-	-	-	-	570	569	568
Liabilities Noncurrent
Convertible Long Term Notes Payable	-	-	-	-	-	-	0	0	557	-	569	-
Contract With Customer Liability Noncurrent	-	-	-	-	-	-	-	-	-	-	0	0
Long Term Line Of Credit	196	195	195	195	98	97	97	97	97	-	0	-
Operating Lease Liability Noncurrent	38	39	42	43	43	40	20	21	22	26	27	22
Other Liabilities Noncurrent	-	-	-	0	0	0	0	0	0	0	0	0
Liabilities Noncurrent	236	240	241	244	147	144	124	126	681	602	605	595
Liabilities	457	457	464	1,020	896	887	881	861	850	762	784	753
Stockholders Equity
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	1,719	1,697	1,634	1,613	1,583	1,555	1,520	1,454	1,423	1,388	1,353	1,334
Accumulated Other Comprehensive Income Loss Net Of…	-3	-5	-3	-6	-5	-4	-6	-5	-4	-4	-5	-2
Retained Earnings Accumulated Deficit	-1,377	-1,361	-1,290	-1,266	-1,229	-1,188	-1,154	-1,088	-1,058	-1,024	-986	-938
Stockholders Equity	338	331	340	341	349	362	360	361	362	359	362	394
Liabilities And Stockholders Equity	795	788	804	1,361	1,246	1,249	1,241	1,222	1,212	1,121	1,146	1,146
Common Stock Shares Issued	116	116	112	112	112	111	109	108	108	108	107	107
Shares Outstanding	116	116	112	112	112	111	109	108	108	108	107	107

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	18.08%	-6.11%	4.67%	-	-	-	-	-	-	-	-	-
2025	-3.56%	-5.39%	-5.12%	-6.46%	-3.11%	7.58%	-6.79%	0.16%	6.40%	-14.11%	-6.69%	27.85%
2024	63.14%	34.39%	29.67%	-4.02%	-0.43%	-15.55%	4.36%	81.28%	54.03%	0.52%	-18.98%	-6.97%
2023	-	-	-	-8.49%	-43.12%	-58.12%	-4.99%	4.15%	2.84%	-8.27%	-10.96%	8.07%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	2.89	2.90	2.90	1.55	1.45	1.47	1.46	1.49	6.46	6.26	5.78	6.67
Quick Ratio	2.70	2.70	2.71	1.50	1.39	1.41	1.42	1.44	6.22	5.99	5.56	6.43
Working Capital	417.81M	414.09M	423.50M	423.85M	333.67M	346.00M	350.18M	360.27M	923.66M	842.48M	855.29M	890.84M
Leverage & Debt
Debt to Equity	1.35	1.38	1.36	2.99	2.57	2.45	2.44	2.39	2.35	2.12	2.16	1.91
Interest Coverage TTM	-15.01	-14.17	-8.24	-6.74	-5.62	-4.51	-4.33	-3.58	-4.21	-5.12	-5.66	-6.09
Debt Ratio	0.57	0.58	0.58	0.75	0.72	0.71	0.71	0.70	0.70	0.68	0.68	0.66
Efficiency & Turnover
Asset Turnover TTM	0.69	0.66	0.64	0.50	0.51	0.52	0.51	0.49	0.46	0.46	0.44	0.43
Days Sales Outstanding TTM	49.34	48.11	45.58	43.27	44.78	43.91	40.84	41.76	45.03	48.58	52.84	55.29
Receivables Turnover TTM	7.40	7.59	8.01	8.43	8.15	8.31	8.94	8.74	8.11	7.51	6.91	6.60
Per Share Metrics
Diluted EPS TTM	-1.28	-1.52	-1.22	-1.59	-1.53	-1.49	-1.56	-1.38	-1.57	-1.80	-1.95	-1.85
Free Cash Flow Per Share TTM	-0.22	-0.42	-0.68	-0.58	-0.72	-0.65	-0.64	-0.72	-0.97	-1.13	-0.94	-0.84
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	76.13%	75.20%	74.54%	75.37%	76.38%	77.16%	77.33%	76.41%	75.82%	74.82%	74.81%	75.27%
Operating Profit Margin TTM	-22.08%	-27.19%	-23.47%	-27.51%	-27.42%	-26.84%	-28.17%	-27.51%	-33.65%	-40.74%	-45.72%	-44.47%
Net Profit Margin TTM	-21.25%	-25.66%	-20.79%	-27.66%	-27.13%	-26.41%	-27.86%	-25.93%	-30.67%	-36.67%	-40.65%	-39.14%
Growth Metrics
Net Revenue Growth (1Y)	10.95%	8.48%	8.28%	11.17%	14.58%	18.27%	18.82%	14.63%	8.33%	0.61%	-5.30%	-7.12%
Net Income Growth (1Y)	-13.09%	5.40%	-19.21%	18.60%	1.33%	-14.82%	-18.55%	-24.07%	-3.25%	36.75%	123.75%	141.49%
EPS Growth (1Y)	-16.42%	1.82%	-21.85%	14.72%	-2.18%	-17.15%	-19.64%	-25.10%	-4.51%	34.71%	120.11%	137.21%
Valuation Metrics
P/E TTM	-11.83	-7.19	-10.58	-8.14	-11.62	-11.97	-19.06	-11.30	-10.94	-8.70	-7.67	-8.74
P/B TTM	5.20	3.76	4.23	4.24	5.68	5.43	8.92	4.69	5.10	4.67	4.38	4.38
P/S TTM	2.51	1.84	2.20	2.25	3.15	3.16	5.31	2.93	3.35	3.19	3.12	3.42
Market Cap	1.76B	1.24B	1.44B	1.45B	1.99B	1.97B	3.21B	1.69B	1.84B	1.68B	1.59B	1.72B
Enterprise Value	1.65B	1.15B	1.34B	1.66B	2.39B	2.40B	3.61B	2.06B	2.23B	1.79B	1.91B	2.14B
Calculated Values
Free Cash Flow TTM	-25.43M	-48.07M	-75.68M	-65.17M	-80.40M	-72.14M	-69.22M	-78.21M	-104.47M	-120.97M	-100.43M	-89.19M
Net Debt	-103.62M	-97.32M	-103.39M	215.98M	407.66M	431.69M	394.39M	368.13M	388.07M	112.29M	326.26M	411.47M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-04Sale

Owner: Leonard, Frank X

Title: Chief Executive Officer

Shares: 34,273

Price/Share: $17.93

Value: $614,514.89

Shares Owned: 459,520

Relationship: Officer

Ownership: Direct

2026-06-02Sale

Owner: Hung, David

Title: -

Shares: 2,945

Price/Share: $15.77

Value: $46,442.65

Shares Owned: 20,465

Relationship: Director

Ownership: Direct

2026-06-02Sale

Owner: Hilleman, Jeryl L

Title: -

Shares: 2,945

Price/Share: $15.77

Value: $46,442.65

Shares Owned: 13,861

Relationship: Director

Ownership: Direct

2026-06-02Sale

Owner: Stafford, Kristin

Title: -

Shares: 2,945

Price/Share: $15.77

Value: $46,442.65

Shares Owned: 11,324

Relationship: Director

Ownership: Direct

2026-06-02Sale

Owner: Ocean, Allyson J

Title: -

Shares: 2,945

Price/Share: $15.77

Value: $46,442.65

Shares Owned: 11,324

Relationship: Director

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-04	Leonard, Frank X	Officer	Chief Executive Officer	Direct	Sale	34,273	17.93	$614,514.89	459,520	4
2026-06-02	Hung, David	Director	-	Direct	Sale	2,945	15.77	$46,442.65	20,465	4
2026-06-02	Hilleman, Jeryl L	Director	-	Direct	Sale	2,945	15.77	$46,442.65	13,861	4
2026-06-02	Stafford, Kristin	Director	-	Direct	Sale	2,945	15.77	$46,442.65	11,324	4
2026-06-02	Ocean, Allyson J	Director	-	Direct	Sale	2,945	15.77	$46,442.65	11,324	4
2026-06-02	Scannell, Timothy J	Director	-	Direct	Sale	2,945	15.77	$46,442.65	14,288	4
2026-06-02	Leung, Gabriel	Director	-	Direct	Sale	2,945	15.77	$46,442.65	89,499	4
2026-06-02	Vernon, W Anthony	Director	-	Direct	Sale	2,945	15.77	$46,442.65	197,657	4
2026-03-05	Paravasthu, Mukund	Officer	Chief Operating Officer	Direct	Sale	43,246	13.77	$595,497.42	72,832	4
2026-03-04	Leupin, Nicolas	Officer	Former Chief Medical Officer	Direct	Sale	1,100	13.31	$14,641.00	102,979	4
2026-03-04	Brackmann, Christoph	Officer	Chief Financial Officer	Direct	Sale	6,412	13.31	$85,343.72	182,842	4
2026-03-04	Weinberg, Uri	Officer	Chf Medical and Innovation Ofr	Direct	Sale	6,412	13.31	$85,343.72	267,190	4
2026-03-04	Puri, Michal Nath	Officer	Chief Human Resources Officer	Direct	Sale	1,100	13.31	$14,641.00	201,322	4
2026-03-04	Leonard, Frank X	Officer	Chief Executive Officer	Direct	Sale	5,607	13.31	$74,629.17	493,793	4
2026-03-03	Doyle, William F	Director,Officer	Executive Chairman	Direct	Sale	71,887	13.11	$942,438.57	328,397	4
2026-03-02	Weinberg, Uri	Officer	Chf Medical and Innovation Ofr	Direct	Sale	3,272	13.33	$43,615.76	223,477	4
2026-03-02	Paravasthu, Mukund	Officer	Chief Operating Officer	Direct	Sale	408	13.49	$5,503.92	76,343	4
2026-03-02	Leonard, Frank X	Officer	Chief Executive Officer	Direct	Sale	7,232	13.49	$97,559.68	349,400	4
2026-02-27	Leupin, Nicolas	Officer	Former Chief Medical Officer	Direct	Sale	1,029	13.66	$14,056.14	104,079	4
2026-02-27	Puri, Michal Nath	Officer	Chief Human Resources Officer	Direct	Sale	1,441	13.66	$19,684.06	162,322	4
2025-09-05	Cordova, Ashley	Officer	Chief Executive Officer	Direct	Purchase	81,550	12.22	$996,541.00	437,569	4
2025-07-29	Brackmann, Christoph	Officer	Chief Financial Officer	Direct	Purchase	20,000	11.58	$231,600.00	141,150	4
2025-06-03	Leung, Gabriel	Director	-	Direct	Sale	999	17.31	$17,292.69	81,229	4
2025-06-03	Ocean, Allyson J	Director	-	Direct	Sale	999	17.29	$17,272.71	3,054	4
2025-06-03	Vernon, W Anthony	Director	-	Direct	Sale	999	17.35	$17,332.65	167,887	4
2025-06-03	Scannell, Timothy J	Director	-	Direct	Sale	999	17.32	$17,302.68	6,018	4
2025-06-03	Madden, Martin J.	Director	-	Direct	Sale	999	17.19	$17,172.81	18,674	4
2025-06-03	Stafford, Kristin	Director	-	Direct	Sale	999	17.28	$17,262.72	3,054	4
2025-06-03	Hung, David	Director	-	Direct	Sale	999	17.30	$17,282.70	12,195	4
2025-06-03	Hilleman, Jeryl L	Director	-	Direct	Sale	999	17.26	$17,242.74	5,591	4
2025-06-02	Leonard, Frank X	Officer	EVP, Pres., Novocure Oncology	Direct	Sale	30,196	18.07	$545,641.72	168,452	4
2025-05-03	Paravasthu, Mukund	Officer	Chief Operating Officer	Direct	Sale	592	17.91	$10,602.72	83,556	4
2025-03-03	Cordova, Ashley	Officer	Chief Executive Officer	Direct	Sale	2,053	18.54	$38,062.62	204,005	4
2025-03-03	Leonard, Frank X	Officer	EVP, Pres., Novocure Oncology	Direct	Sale	2,527	18.54	$46,850.58	143,673	4
2025-03-03	Weinberg, Uri	Officer	Chief Innovation Officer	Direct	Sale	268	18.92	$5,070.56	166,243	4
2025-03-03	Paravasthu, Mukund	Officer	Chief Operating Officer	Direct	Sale	250	18.54	$4,635.00	29,173	4
2025-02-28	Weinberg, Uri	Officer	Chief Innovation Officer	Direct	Sale	4,637	18.55	$86,016.35	166,511	4/A
2025-02-28	Cordova, Ashley	Officer	Chief Executive Officer	Direct	Sale	2,341	18.28	$42,793.48	206,058	4/A
2025-02-28	Leonard, Frank X	Officer	EVP, Pres., Novocure Oncology	Direct	Sale	2,770	18.28	$50,635.60	146,200	4/A
2025-02-28	Paravasthu, Mukund	Officer	Chief Operating Officer	Direct	Sale	368	18.28	$6,727.04	29,423	4/A
2025-02-27	Leupin, Nicolas	Officer	Chief Medical Officer	Direct	Sale	991	20.24	$20,057.84	50,133	4/A
2025-02-27	Puri, Michal Nath	Officer	Chief Human Resources Officer	Direct	Sale	1,387	20.24	$28,072.88	108,706	4/A
2025-01-11	Paravasthu, Mukund	Officer	Chief Operating Officer	Direct	Sale	2,160	26.81	$57,909.60	31,437	4
2024-11-02	Paravasthu, Mukund	Officer	Chief Operating Officer	Direct	Sale	44	16.69	$734.36	3,459	4
2024-11-01	Paravasthu, Mukund	Officer	Chief Operating Officer	Direct	Sale	160	15.88	$2,540.80	3,503	4
2024-11-01	Leonard, Frank X	Officer	EVP, Pres., Novocure Oncology	Direct	Sale	598	15.94	$9,532.12	161,236	4
2024-10-31	Puri, Michal Nath	Officer	Chief Human Resources Officer	Direct	Sale	810	15.79	$12,789.90	110,093	4
2024-08-02	Cordova, Ashley	Officer	Chief Financial Officer	Direct	Sale	688	20.14	$13,856.32	219,179	4
2024-06-04	Leung, Gabriel	Director	-	Direct	Sale	964	23.89	$23,029.96	78,175	4
2024-06-04	Vernon, W Anthony	Director	-	Direct	Sale	964	23.89	$23,029.96	164,833	4
2024-06-04	Scannell, Timothy J	Director	-	Direct	Sale	964	23.89	$23,029.96	2,964	4
2024-03-04	Groenhuysen, Wilhelmus Cm	Officer	Chief Operating Officer	Direct	Sale	1,217	16.01	$19,484.17	251,235	4
2024-03-04	Leonard, Frank X	Officer	EVP, Pres., Novocure Oncology	Direct	Sale	840	16.01	$13,448.40	160,098	4
2024-02-28	Groenhuysen, Wilhelmus Cm	Officer	Chief Operating Officer	Direct	Sale	2,303	16.14	$37,170.42	254,559	4
2024-02-28	Leonard, Frank X	Officer	EVP, Pres., Novocure Oncology	Direct	Sale	2,078	16.14	$33,538.92	162,617	4
2023-11-07	Shah, Pritesh	Officer	Chief Growth Officer	Direct	Sale	382	12.65	$4,832.30	124,511	4
2023-09-01	Groenhuysen, Wilhelmus Cm	Officer	Chief Operating Officer	Direct	Sale	294	21.82	$6,415.08	209,825	4
2023-09-01	Cordova, Ashley	Officer	Chief Financial Officer	Direct	Sale	883	21.82	$19,267.06	99,650	4
2023-09-01	Shah, Pritesh	Officer	Chief Growth Officer	Direct	Sale	273	21.82	$5,956.86	124,893	4
2023-08-02	Cordova, Ashley	Officer	Chief Financial Officer	Direct	Sale	1,144	30.25	$34,606.00	100,533	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

81.89%

Inst. Shares: 93,475,669

Shares Outstanding: 114,149,838

2025-12-31

82.55%

Inst. Shares: 92,023,794

Shares Outstanding: 111,471,991

2025-09-30

78.25%

Inst. Shares: 87,568,496

Shares Outstanding: 111,908,252

2025-06-30

82.33%

Inst. Shares: 91,860,917

Shares Outstanding: 111,572,191

2025-03-31

84.64%

Inst. Shares: 93,338,396

Shares Outstanding: 110,281,832

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	93,475,669	114,149,838	81.89%
2025-12-31	92,023,794	111,471,991	82.55%
2025-09-30	87,568,496	111,908,252	78.25%
2025-06-30	91,860,917	111,572,191	82.33%
2025-03-31	93,338,396	110,281,832	84.64%
2024-12-31	86,735,563	107,834,368	80.43%
2024-09-30	86,087,481	108,247,716	79.53%
2024-06-30	87,291,859	107,700,284	81.05%
2024-03-31	84,401,929	107,266,198	78.68%
2023-12-31	86,255,131	106,391,178	81.07%
2023-09-30	87,527,891	106,772,814	81.98%
2023-06-30	84,142,777	106,289,073	79.16%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

NovoCure Ltd (NVCR) — SEC Financial Statements & Analysis

NovoCure Ltd (NVCR) is a surgical & medical instruments & apparatus company. NovoCure Ltd trades on Nasdaq as: NVCR. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), NovoCure Ltd reported a 10.95% year-over-year revenue growth, a Gross Profit Margin of 76.13% (TTM), a Debt-to-Equity ratio of 1.35x, a Price-to-Sales (P/S) ratio of 2.51x (TTM), a Price-to-Book (P/B) ratio of 5.20x (TTM), at a market cap of $1.76B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 10.95%
Gross Profit Margin TTM: 76.13%
Debt To Equity: 1.35x
P/S TTM: 2.51x
P/B TTM: 5.20x
Market Cap: $1.76B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is NovoCure Ltd in?

NovoCure Ltd (NVCR) operates in the Surgical & Medical Instruments & Apparatus industry.

What is NVCR's market cap?

NovoCure Ltd (NVCR) has a market capitalization of $1.76B as of 2026-06-30.

What exchange does NVCR trade on?

NovoCure Ltd (NVCR) trades on the Nasdaq.

NovoCure Ltd

Financial Statements

Custom Table

Interactive Financial Visualizations

Earnings Market Reaction

Performance and Valuation Metrics

Insider Transactions

Institutional Ownership

NovoCure Ltd (NVCR) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Surgical & Medical Instruments & Apparatus

Wall Street's data.
Main Street's price.

NovoCure Ltd (NVCR) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Surgical & Medical Instruments & Apparatus

Wall Street's data.Main Street's price.

Wall Street's data.
Main Street's price.